01:55 , Oct 13, 2018 |  BioCentury  |  Product Development

Bourla’s breadcrumbs to value

Incoming CEO Albert Bourla has spent only a few of his 25 years at Pfizer Inc. in the pharma’s innovative drugs business, but there are signs he already has laid the groundwork for innovating how...
23:20 , Oct 5, 2018 |  BioCentury  |  Finance

Fruitful partnerships

Arix Bioscience plc (LSE:ARIX) leveraged its partnership with Takeda Ventures to co-lead a $58 million series A round for antibody-drug company VelosBio Inc., a sign that the VC’s strategic partnerships are finally bearing fruit. Also participating...
19:46 , Oct 5, 2018 |  BC Week In Review  |  Company News

Nektar falls on short seller report

Nektar Therapeutics Inc. (NASDAQ:NKTR) fell $4.31 to $56.65 on Oct. 1 after short seller Plainview LLC released a report calling the value of the biotech's NKTR-214 zero. Nektar lost more than $740 million in market...
20:47 , Oct 3, 2018 |  BC Extra  |  Politics & Policy

U.K. hints at new NHS cancer strategy, announces genomic healthcare service

U.K. Prime Minister Theresa May said in a speech Wednesday that NHS will aim to increase early cancer diagnosis as part of its upcoming 10 year plan. The U.K. government first announced the 2019-29 plan...
23:48 , Oct 1, 2018 |  BC Extra  |  Clinical News

Nektar falls on short seller report

Nektar Therapeutics Inc. (NASDAQ:NKTR) fell $4.31 to $56.65 on Monday after short seller Plainview LLC released a report calling the value of the biotech's NKTR-214 zero. Nektar lost more than $740 million in market cap...
19:44 , Sep 14, 2018 |  BioCentury  |  Emerging Company Profile

Laekna’s jumping off place

Chinese biotech Laekna Therapeutics Shanghai Co. Ltd. is jump-starting its pipeline with a trio of clinical cancer compounds from Novartis AG. The safety of the lead candidate and its potential to synergize with the other...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
02:58 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

Stepping Through

Once considered obstacles to biomedical product development, regulators around the world have become enablers of the kinds of scientific and economic innovations that will underpin new business models. They are building gateways that could help...
18:55 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Sensyne proposes London IPO

Data analysis company Sensyne Health plc (Oxford, U.K.) proposed to raise £60 million ($78 million) in an IPO on the London Stock Exchange's AIM market. The company expects to begin trading on Aug. 17. Sensyne uses...
22:54 , Aug 7, 2018 |  BC Extra  |  Financial News

Sensyne proposes London IPO

Data analysis company Sensyne Health plc (Oxford, U.K.) proposed to raise £60 million ($78 million) in an IPO on the London Stock Exchange's AIM market. The company expects to begin trading on Aug. 17. Sensyne uses...